Basic Behavioral and Social Science Opportunity Network (OppNet), 65363 [2010-26709]
Download as PDF
<![CDATA[
emcdonald on DSK2BSOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 204 / Friday, October 22, 2010 / Notices
manufactured by SmithKline Beecham
Corp. d/b/a (doing business as)
GlaxoSmithKline and 020–180/S–034,
trade name PROSCAR (finasteride)
Tablets, manufactured by Merck & Co.,
Inc. The proposed indication (use) for
AVODART (dutasteride) is for reduction
in the risk of prostate cancer in men at
increased risk of developing the disease.
The population at increased risk of
prostate cancer includes men with an
elevated serum prostate-specific antigen
(PSA) or men otherwise determined to
be at increased risk based on other
associated risk factors such as age, race,
and family history. There is no
proposed expansion of the indication
for PROSCAR (finasteride); however, in
light of the Prostate Cancer Prevention
Trial (PCPT) which demonstrated a
statistically significant reduction in the
7-year period prevalence of prostate
cancer with finasteride (PROSCAR)
treatment, and which reported an
imbalance in high Gleason grade
prostate cancers (indicating more
aggressive cancers) in the finasteride
treatment arm vs. placebo, the efficacy
and safety of both products for use in
prostate cancer risk reduction will be
examined.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before November 16, 2010.
Oral presentations from the public will
be scheduled between approximately
2:30 p.m. to 3:30 p.m. Those desiring to
make formal oral presentations should
notify the contact person and submit a
brief statement of the general nature of
the evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before November 8, 2010. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
VerDate Mar<15>2010
17:43 Oct 21, 2010
Jkt 223001
FDA may conduct a lottery to determine
the speakers for the scheduled open
public hearing session. The contact
person will notify interested persons
regarding their request to speak by
November 9, 2010.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Nicole
Vesely at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: October 13, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–26651 Filed 10–21–10; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Basic Behavioral and Social Science
Opportunity Network (OppNet)
ACTION:
Notice.
A two-day meeting
highlighting OppNet’s activities and
future goals is scheduled for Thursday,
October 28, and Friday, October 29,
2010, at the Hyatt Regency Washington
on Capitol Hill, 400 New Jersey Avenue,
NW., Washington DC 20001. This is the
first public meeting to promote and
publicize the Basic Behavioral and
Social Science Opportunity Network
(OppNet) initiative. Attendance is
limited to prior registration via https://
www.regonline.com/oppnet.
Background: The Basic Behavioral
and Social Science Opportunity
Network (OppNet) is a trans-NIH
initiative to expand the agency’s
funding of basic behavioral and social
sciences research (b-BSSR). OppNet
prioritizes activities and initiatives that
focus on basic mechanisms of behavior
SUMMARY:
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
65363
and social processes that are relevant to
the missions and public health
challenges of multiple NIH Institutes,
Centers, and Offices (ICOs) and that
build upon existing NIH investments
without replicating them. https://
www.oppnet.nih.gov.
Participating: The meeting will take
place on October 28, from 9 a.m. to 4:30
p.m., and October 29, from 8:30 a.m. to
2:30 p.m., at the Hyatt Regency
Washington on Capitol Hill, 400 New
Jersey Avenue, NW., Washington DC
20001.
FOR FURTHER INFORMATION CONTACT: To
register, visit the registration Web site at
https://regonline.com/oppnet, call
William Elwood at 301–402–0116, or email elwoodwi@od.nih.gov.
Dated: October 15, 2010.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes
of Health.
[FR Doc. 2010–26709 Filed 10–21–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Review of Minority Biomedical
Research Neuro Grant Applications.
Date: December 6, 2010.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency-Bethesda, 7400
Wisconsin Avenue, One Bethesda Metro
Center, Bethesda, MD 20814.
Contact Person: John J. Laffan, PhD,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health,
Natcher Building, Room 3AN18J, Bethesda,
MD 20892, 301–594–2773,
laffanjo@mail.nih.gov.
E:\FR\FM\22OCN1.SGM
22OCN1
]]>Agencies
[Federal Register Volume 75, Number 204 (Friday, October 22, 2010)]
[Notices]
[Page 65363]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-26709]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Basic Behavioral and Social Science Opportunity Network (OppNet)
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: A two-day meeting highlighting OppNet's activities and future
goals is scheduled for Thursday, October 28, and Friday, October 29,
2010, at the Hyatt Regency Washington on Capitol Hill, 400 New Jersey
Avenue, NW., Washington DC 20001. This is the first public meeting to
promote and publicize the Basic Behavioral and Social Science
Opportunity Network (OppNet) initiative. Attendance is limited to prior
registration via https://www.regonline.com/oppnet.
Background: The Basic Behavioral and Social Science Opportunity
Network (OppNet) is a trans-NIH initiative to expand the agency's
funding of basic behavioral and social sciences research (b-BSSR).
OppNet prioritizes activities and initiatives that focus on basic
mechanisms of behavior and social processes that are relevant to the
missions and public health challenges of multiple NIH Institutes,
Centers, and Offices (ICOs) and that build upon existing NIH
investments without replicating them. https://www.oppnet.nih.gov.
Participating: The meeting will take place on October 28, from 9
a.m. to 4:30 p.m., and October 29, from 8:30 a.m. to 2:30 p.m., at the
Hyatt Regency Washington on Capitol Hill, 400 New Jersey Avenue, NW.,
Washington DC 20001.
FOR FURTHER INFORMATION CONTACT: To register, visit the registration
Web site at https://regonline.com/oppnet, call William Elwood at 301-
402-0116, or e-mail elwoodwi@od.nih.gov.
Dated: October 15, 2010.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes of Health.
[FR Doc. 2010-26709 Filed 10-21-10; 8:45 am]
BILLING CODE 4140-01-P
